- Home
- GILD vs ISRG Comparison
GILD vs ISRG Comparison
Compare GILD & ISRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ISRG
- Stock Information
- Founded
- GILD 1987
- ISRG 1995
- Country
- GILD United States
- ISRG United States
- Employees
- GILD N/A
- ISRG N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ISRG Medical/Dental Instruments
- Sector
- GILD Health Care
- ISRG Health Care
- Exchange
- GILD Nasdaq
- ISRG Nasdaq
- Market Cap
- GILD 147.6B
- ISRG 154.0B
- IPO Year
- GILD 1992
- ISRG 2000
- Fundamental
- Price
- GILD $127.67
- ISRG $574.62
- Analyst Decision
- GILD Buy
- ISRG Buy
- Analyst Count
- GILD 22
- ISRG 15
- Target Price
- GILD $123.45
- ISRG $595.47
- AVG Volume (30 Days)
- GILD 7.6M
- ISRG 2.0M
- Earning Date
- GILD 10-30-2025
- ISRG 10-21-2025
- Dividend Yield
- GILD 2.48%
- ISRG N/A
- EPS Growth
- GILD 6514.05
- ISRG 21.56
- EPS
- GILD 6.42
- ISRG 7.56
- Revenue
- GILD $29,087,000,000.00
- ISRG $9,612,000,000.00
- Revenue This Year
- GILD $3.05
- ISRG $20.98
- Revenue Next Year
- GILD $3.29
- ISRG $15.11
- P/E Ratio
- GILD $19.85
- ISRG $75.98
- Revenue Growth
- GILD 2.79
- ISRG 22.18
- 52 Week Low
- GILD $88.57
- ISRG $425.00
- 52 Week High
- GILD $128.70
- ISRG $616.00
- Technical
- Relative Strength Index (RSI)
- GILD 60.74
- ISRG 64.80
- Support Level
- GILD $124.49
- ISRG $548.04
- Resistance Level
- GILD $128.25
- ISRG $574.45
- Average True Range (ATR)
- GILD 3.43
- ISRG 14.50
- MACD
- GILD 0.17
- ISRG -1.59
- Stochastic Oscillator
- GILD 91.36
- ISRG 82.70
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.